- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.11. | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 | 205 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 29.10. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.10. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date | 151 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 15.10. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.10. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 | 294 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 16.09. | Revelation Biosciences files to sell 13.07M shares of common stock by selling shareholders | 4 | Seeking Alpha | ||
| 11.09. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds | 284 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 10.09. | Revelation Biosciences: Wirkstoffkandidat Gemini zeigt vielversprechende Ergebnisse bei chronischer Nierenerkrankung | 2 | Investing.com Deutsch | ||
| 10.09. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data | 354 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
| 09.09. | Revelation Biosciences, Inc.: Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data | 273 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 09.09. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 09.09. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study | 211 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
| 08.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 09.07. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.07. | Revelation Biosciences to implement 1-for-3 reverse stock split | 1 | Investing.com | ||
| 01.07. | Revelation Biosciences plant Aktienzusammenlegung im Verhältnis 1:3 | 1 | Investing.com Deutsch | ||
| 01.07. | Revelation Biosciences, Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 | 206 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of... ► Artikel lesen | |
| 25.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 4 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 35,000 | -2,70 % | Structure Therapeutics stock holds Outperform rating at BMO ahead of key data | ||
| BEAM THERAPEUTICS | 21,660 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,860 | -2,39 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| AVIDITY BIOSCIENCES | 70,81 | -0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,260 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 33,810 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 44,290 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| ANNEXON | 2,680 | 0,00 % | Annexon prices public offering of shares at $2.60 each | ||
| ARS PHARMACEUTICALS | 8,410 | -5,98 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| LENZ THERAPEUTICS | 26,510 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| UPSTREAM BIO | 23,340 | 0,00 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| ARCELLX | 87,28 | -3,18 % | J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T | ||
| PRAXIS PRECISION MEDICINES | 178,20 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,325 | 0,00 % | Change at the top of Recursion as co-founder leaves CEO role | ||
| BIONTECH | 89,95 | +0,73 % | BioNTech: Analysten sehen Aktie nach Zahlen im neuen Licht | Die jüngsten Quartalszahlen von BioNTech führten in dieser Woche zu unterschiedlichen Einschätzungen zweier Analystenhäuser. Während UBS das Kursziel leicht anhebt, bleibt Jefferies deutlich positiver.... ► Artikel lesen |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,90 % bei einem Aktienkurs von 0,922 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.